Two new sites will help with mass testing needs. Photo by Getty Images

With the omicron variant showing no signs of slowing locally or nationally, the City of Houston’s health department has partnered with a major company to open two mega COVID-19 testing sites this week, both opening on Thursday, January 6.

Those near Greater Houston can look for a new mega testing site at the former Dave & Busters at 6010 Richmond Ave. Opened in partnership with Xpress COVID Testing, this new site will accommodate approximately 1,000 tests, per an announcement. January hours of operation are 9 am to 3:30 pm Mondays through Saturdays; appointments are not required.

Those outside Greater Houston to the north can look for a new site at the Kingwood Community Center (4102 Rustic Woods Dr.); its daily capacity is approximately 800 tests. January hours here are 9 am to 3:30 pm Mondays through Saturdays’ appointments are not required.

Meantime, existing mega testing sites are operating at the following locations:

Butler Stadium (13755 S Main St).
Hours are 8 am to 4 pm Mondays through Saturdays with no appointment required.

Delmar Stadium (2020 Mangum Rd.)
Hours are 8 am to 6 pm daily; appointments are required and can be made at appointments via Curative.com or by calling 1-888-702-9042.

Minute Maid Park
Minute Maid Park (Lot C, 510 St. Emanuel St.)
Hours are 8 am to 5 pm on Saturdays, Mondays, Tuesdays, Wednesdays; noon to 8 pm on Thursdays and Fridays. Appointments are required at mycovidappoitment.com or by calling 833-213-0643.

More testing sites, schedules, and appointment information are available at HoustonHealth.org or by calling 832-393-4220.

“Every Houstonian deserves to have access to testing, especially those in our most vulnerable communities,” said Mayor Sylvester Turner in a statement. “As we continue to navigate this crisis, I ask Houstonians to keep each other safe by getting tested, vaccinated, and boosted. We need everyone doing their part to remain healthy and slow the virus from spreading in their homes and places of employment and houses of worship.”

------

This article originally ran on CultureMap.

The new mega-site opens December 29. valentinrussanov/Getty Images

City of Houston announces massive new drive-through COVID testing site

new to hou

With COVID/omicron cases on the rise and Houston preparing for New Year’s Eve celebrations and travel, the City of Houston is expanding access to testing with a new drive-through mega site this week.

The site, which comes via the Houston Health Department and Curative, is located at Delmar Stadium, 2020 Mangum Rd., and opens 9 am Wednesday, December 29. Hours of operation run 8 am to 6 pm; the site promises to handle some 1,000 daily tests, according to a press release. Appointments are required at Curative.com or by calling 1-888-702-9042.

Importantly, the mega-site will be closed December 31 and January 1, 2022.

This means that at full capacity, the department’s network of Curative, United Memorial Medical Center, and multi-service center sites can provide approximately 27,000 daily tests.

Those interested can still visit HoustonHealth.org or call 832-393-4220 to find nearby free health department-affiliated testing sites and schedules.

Current Centers for Disease Control recommendations dictate that those who have symptoms and anyone who had close contact (within 6 feet for a total of 15 minutes or more over a 24-hour period) with someone with confirmed COVID-19 should test for infection.

Testing and vaccination at health department-affiliated sites is free, and does not require proof of residency, citizenship, or insurance.

“As Omicron cases surge in Houston and across the country, I applaud people for getting tested before traveling, gathering with loved ones or returning to work,” said Mayor Sylvester Turner in a statement. “Testing and vaccination will help slow the virus spread and save lives. The increased demand for testing has led to longer than usual lines and wait times for some. The new site will help meet the demand and expand capacity for testing.”

------

This article originally ran on CultureMap.

Luminostics, which was founded out of a lab at UH, received NIH grant to produce its COVID-19 rapid antigen test. Photo courtesy of Luminostics

University of Houston spinout's smartphone COVID-19 test to head to market

Pandemic innovation

A Silicon Valley startup with Houston roots is helping tackle the COVID-19 pandemic with its smartphone-based coronavirus test.

Milpitas, California-based Luminostics, a University of Houston spinout, is producing millions of its Clip COVID Rapid Antigen Test for U.S. consumers after receiving emergency authorization for the product in December. The emergency approval closely followed the National Institutes of Health awarding a $26.1 million contract to Luminostics to speed up development of the coronavirus test. According to a news release from UH, Luminostics is working on an affordable next generation hardware system to reach the mass over-the-counter market at scale.

Chemical engineers and UH alumni Bala Raja, the CEO, and Andrew Paterson, the chief technology officer, began forming their company in the UH lab of Richard Willson, a professor of chemical and biomolecular engineering and professor of biochemical and biophysical sciences.

The technology developed in the UH lab aims to equip consumers with rapid self-diagnostic tests for the flu, HIV, herpes, and other conditions by detecting the presence of bacteria, viruses, small molecules, hormones, and proteins. But Raja and Paterson put that strategy on hold last year and pivoted to re-engineering their technology for COVID-19 testing. The result: the Clip COVID Rapid Antigen Test.

"When we realized that COVID wasn't just a bad flu and that it was actually gonna go crazy and affect as many people as it has, we decided that everything we've done could be very quickly repurposed to make two different tests," Raja told Inc. magazine in April.

UH alumni Andrew Paterson and Bala Raja are co-founders of Luminostics. Photo via UH.edu

As UH explains, the Clip COVID test relies on a nasal swab, a smartphone clip, and glow-in-the-dark nanoparticles to detect a coronavirus infection within 30 minutes. In the phone, an image processor measures the intensity of the luminescence signal. If the signal is strong enough, the result is positive. If it's weak, the result is negative.

"We live in a world where you can have all your basic necessities delivered to your home through an app, and yet this pandemic has exposed how far behind the diagnostics industry lags compared to consumer technology and the convenience economy," Paterson tells UH.

Funding from the National Institutes of Health, venture capital firm Khosla Ventures, investment firm Lynette Capital, and startup accelerator Y Combinator has helped support the Clip COVID Rapid Antigen Test. The startup entered the Y Combinator program in 2016, a year after Raja and Paterson established Luminostics.

In April 2020, French pharmaceutical giant Sanofi said it was exploring a collaboration with Luminostics on the COVID-19 test.

"The diagnostics industry is saturated with products that cater to big, centralized labs or testing in the doctor's office," Paterson says. "There are many applications where it does make sense to do testing in a centralized lab, but there are dozens of other applications where there should be home-tests and there are not, because few companies have tried to take on the technical and regulatory challenges with developing home-testing."

A Houston entrepreneur created a free smartphone app to easily track and share COVID-19 testing results. Photo courtesy of SafeFun

Houston tech-turned-hospitality entrepreneur launches global health passport

there's an app for that

The pandemic brought Houston hospitality entrepreneur Carson Hager — a self-described "recovering programmer" — back to his roots in an attempt to help people gather together once more.

After 20 years in the tech world — he sold his consumer-grade commercial software company Cynergy Systems to KPMG in 2014 —Hager founded the Hospitable Viking, known for popular local bars like Rosemont in Montrose and Cherry downtown.

"It gives me some chaos," he says of his new industry. "It's something to do that's a very different challenge."

But the pandemic added a new challenge and even more chaos in his industry. As restrictions were put in place in the spring of 2020 and many (including Hager himself) didn't feel comfortable dining and drinking in public, he watched as many in his industry lost their jobs, businesses, and sense of community.

"I live in restaurants and bars and I wouldn't have gone anywhere at that point," Hager says. "I was thinking, what's it going to take for people to be able to feel comfortable to go back out again and go out to bars and restaurants, gyms, salons, club, etcetera."

In April 2020, he decided to act. And with the help of a few programmer friends pulling long hours for about 100 days straight, Hager created SafeFun, a Houston-based digital health passport that allows users to voluntarily and easily share COVID-19 test results and information.

The free app extracts and analyzes PDF test results from a variety of COVID-19 tests including molecular/diagnostic, antigen and antibody tests. SafeFun then validates the test against records from 100 partnering testing centers, including the likes of Walgreens, CVS, and Walmart, to ensure that the results are credible and summarizes the information for users to easily share through the app or in person.

After completing the build out in September 2020, Hager and his small team of four approached various city governments with the hopes of having them come on board as partners and support using the app for business purposes. However, what they found was that users were more interested in using SafeFun for personal reasons.

After a few more weeks of programming, Hager and team released the consumer-facing version in late 2020. Currently SafeFun has about 12,000 users around the world, according to Hager. Today it's mainly used ahead of a small gathering with friends, when visiting family, or to date.

SafeFun also has the capability to process and analyze proof of vaccine and other tests for infectious diseases. However, the current road block in the COVID realm is that in the U.S. most vaccine providers do not provide digital for PDF documentation.

Still, Hager envisions various potential uses for SafeFun in the future: for cruises, air travel, and even STD testing. Or, as Hager says, "God forbid, future pandemics."

Results are generally ready within 30 minutes. Photo courtesy of CVS Health

4 Houston-area CVS locations now offering free COVID-19 rapid tests

COVID-19 NEWS

Flu season and cedar fever compounded with the ongoing COVID-19 pandemic is likely to make for a worrisome winter. In an effort to make testing for the novel coronavirus more accessible, CVS is launching rapid-result tests in 21 stores across the state, including four in Houston.

The Rhode Island-based health company announced its COVID-19 testing expansion on October 28, adding that it hopes to offer the service at 1,000 clinics nationwide by the end of the year.

In the Greater Houston area, COVID-19 rapid-result tests are available at the following CVS stores beginning this week:

  • 1410 Crabb River Rd. in Richmond
  • 3505 Center St. in Deer Park
  • 2232 Repsdorph Rd. in Seabrook
  • 23865 FM 1314 in Porter

Test results are usually available within 30 minutes. Rapid-result COVID-19 tests are available at no cost to patients who meet Centers for Disease Control and Prevention criteria, for those with private insurance, or those insured by the U.S. Department of Health and Human Services, notes a release. Read more about testing costs here.

Patients must register in advance at CVS.com in order to obtain a rapid-result test. Tests are also available for patients ages 12-17, but they must have a parent or guardian fill out the testing information. Children under 15 must be accompanied by an adult to the testing site.

Once at the site, patients should remain in their vehicle and proceed to a designated site located in the parking lot. In rare occasions, the test will take place inside the store, so follow signage and instructions.

"Access to rapid-result tests enables us to help minimize community spread of COVID-19 by being able to more quickly identify active COVID-19 infection," says Dr. David Fairchild, chief medical officer at MinuteClinic, in a news release. "In addition, we can test and treat symptomatic patients who test negative for COVID-19 for seasonal illnesses such as flu or strep and provide appropriate treatment and care."

Earlier this year, CVS expanded its COVID-19 response with drive-thru service in 33 states across the U.S., including Texas. The company's latest offering comes amid a nationwide spike in coronavirus cases, including 500,000 new cases in the last week alone. As of October 26, Texas had more than 874,000 confirmed cases and 17,595 deaths.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”